Next Article in Journal
Genetic Inactivation of Peroxiredoxin-I Impairs the Growth of Human Pancreatic Cancer Cells
Previous Article in Journal
Effect of Preconception Selenium Intake on the Risk for Gestational Diabetes: The Japan Environment and Children’s Study
Previous Article in Special Issue
NQO1 Deficiency Aggravates Renal Injury by Dysregulating Vps34/ATG14L Complex during Autophagy Initiation in Diabetic Nephropathy
Open AccessArticle

The Role of Oxidative Stress Markers in Predicting Acute Thrombotic Occlusion of Haemodialysis Vascular Access and Progressive Stenotic Dysfunction Demanding Angioplasty

by 1,2,3,4, 1,2,3,5,*, 1,2,3 and 6,7,*
1
Department of Internal Medicine, Division of Nephrology, Armed Forces Taoyuan General Hospital, Taoyuan 325, Taiwan
2
Department of Medicine, Division of Nephrology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
3
National Defense Medical Center, School of Medicine, Taipei 114, Taiwan
4
Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan
5
Department of Life Sciences, National Central University, Taoyuan 320, Taiwan
6
Department of Medicine, Division of Nephrology and Hypertension, University of North Carolina, Chapel Hill, NC 27599, USA
7
Salisbury VA Medical Center, Salisbury, NC 27284, USA
*
Authors to whom correspondence should be addressed.
Academic Editors: Natalia Di Pietro and Mario Bonomini
Antioxidants 2021, 10(4), 569; https://doi.org/10.3390/antiox10040569
Received: 2 March 2021 / Revised: 30 March 2021 / Accepted: 3 April 2021 / Published: 8 April 2021
Haemodialysis vascular access (VA) dysfunction is a major cause of morbidity in haemodialysis (HD) patients. Primary venous outflow occlusion and restenosis after percutaneous transluminal angioplasty (PTA) are two major obstacles for the long-term use of dialysis VA. It remains unclear whether oxidative stress markers can be used as predictors for thrombotic occlusion of VA and progressive stenosis dysfunction demanding PTA. All routine HD patients at one teaching hospital participated in this study including ankle-brachial index (ABI) examinations and serum oxidative stress markers. The serum oxidative stress markers (high-sensitivity C-reactive protein (hs-CRP), matrix metalloproteinase-2 (MMP-2), MMP-9, homocysteine, asymmetrical dimethylarginine (ADMA), nitrate oxidase (NO), tumour necrosis factor-α (TNF-α), monocyte chemotactic protein 1 (MCP-1), interleukin-1β (IL-1β), and transforming growth factor-β (TGF-β)) were measured using immunosorbent assays in 159 HD patients (83 men and 76 women; mean age: 65 ± 12 years). The participants met the following criteria: (1) received regular HD treatment for at least 6 months, without clinical evidence of acute or chronic inflammation, recent myocardial infarction, unstable angina or circulatory congestion; and (2) received an arteriovenous fistula (AVF)/arteriovenous graft (AVG: polytetrafluoroethylene, PTFE) as the current VA for more than 6 months, without interventions within the last 6 months. All the participants were followed up clinically for up to 12 months to estimate the amount of primary thrombotic occlusion and VA dysfunction demanding PTA. During the 12-month observation, 24 patients (15.1%) had primary thrombotic occlusion of VAs. Another 24 patients (15.1%) required PTA because of clinical dysfunction of access. Additionally, during the follow-up period, restenosis occurred in 12 patients (50% of 24 patients). The access types of arteriovenous grafts (AVGs) and a diagnosis of peripheral arterial occlusive disease (PAOD) were two strong predictors for acute thrombotic events of VA (hazard ratio (HR): 16.93 vs. 2.35; p < 0.001 vs. 0.047). Comparing dysfunctional with non-dysfunctional VAs, up to 27.7% of patients with high levels of ADMA (>0.6207 μM, N = 65) received required PTA compared with 4.4% of those with low levels (≤0.6207 μM; N = 90; p < 0.001). In multivariate analysis, the plasma baseline levels of ADMA independently conferred nearly 4.55 times the risk of primary stenotic dysfunction of HD VA (HR: 4.55; 95% confidence interval: 1.20 to 17.26; p = 0.026). In conclusion, our findings suggest the role of ADMA in the development of symptomatic VA dysfunction. Additionally, PAOD severity can be used in clinical practice to predict whether acute thrombotic occlusion of VA will easily occur in HD patients. View Full-Text
Keywords: haemodialysis vascular access; vascular access dysfunction; oxidative stress markers; asymmetrical dimethylarginine (ADMA); peripheral arterial occlusive disease haemodialysis vascular access; vascular access dysfunction; oxidative stress markers; asymmetrical dimethylarginine (ADMA); peripheral arterial occlusive disease
Show Figures

Figure 1

MDPI and ACS Style

Chan, J.-S.; Hsiao, P.-J.; Chiang, W.-F.; Roy-Chaudhury, P. The Role of Oxidative Stress Markers in Predicting Acute Thrombotic Occlusion of Haemodialysis Vascular Access and Progressive Stenotic Dysfunction Demanding Angioplasty. Antioxidants 2021, 10, 569. https://doi.org/10.3390/antiox10040569

AMA Style

Chan J-S, Hsiao P-J, Chiang W-F, Roy-Chaudhury P. The Role of Oxidative Stress Markers in Predicting Acute Thrombotic Occlusion of Haemodialysis Vascular Access and Progressive Stenotic Dysfunction Demanding Angioplasty. Antioxidants. 2021; 10(4):569. https://doi.org/10.3390/antiox10040569

Chicago/Turabian Style

Chan, Jeng-Shyong; Hsiao, Po-Jen; Chiang, Wen-Fang; Roy-Chaudhury, Prabir. 2021. "The Role of Oxidative Stress Markers in Predicting Acute Thrombotic Occlusion of Haemodialysis Vascular Access and Progressive Stenotic Dysfunction Demanding Angioplasty" Antioxidants 10, no. 4: 569. https://doi.org/10.3390/antiox10040569

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop